Founded in 2001 with the goal of developing innovative antibody-based therapeutics to treat cancer, the name ABXIS is a reflection of our dedication to become an axis of antibody (Ab) therapeutics.
Our pipeline also includes rare disease therapeutics, in addition to the anti-cancer therapeutics that we developed on our way to becoming a leading biotechnology company in Korea. By providing new ways of combatting cancer and rare diseases, ISU ABXIS will fulfill its vision of enhancing the lives and easing the suffering of patients worldwide.
ISU ABXIS is a biotechnology company dedicated to the development of new and novel bio-therapeutics that will enhance the lives and ease the suffering of patients struggling with cancer and rare diseases.
Creating a beautiful future with abundance and convenience
Developed the 1st Antibody Drug in South Korea
Launched 3 Products Developed Independently
Research Focused on Oncology and Rare Disease
6 Projects in the R&D Pipeline
GMP Manufacturing Facility Operation of 3 Suites